, Etsushi Kuroda 1,2 and Ken J Ishii 1, 2 Innate immune sensing of nucleic acids derived from invading pathogens or tumor cells via pattern recognition receptors is crucial for mounting protective immune responses against infectious disease and cancer. Recently, discovery of tremendous amounts of nucleic acid sensors as well as identification of natural and synthetic ligands for these receptors revealed the potential of adjuvants targeting nucleic acid sensing pathways for designing efficacious vaccines. Especially, current data indicated that unique adjuvants targeting TLR9 and stimulator of interferon genes (STING)-dependent cytosolic nucleic acid sensing pathways along with the combinations of already existing adjuvants are promising candidates for this purpose. Here, we review current vaccine adjuvants targeting nucleic acid sensors and their modes of action.
Introduction
As the provider of first line of defense against invading pathogens or stress, innate immunity utilizes several pattern recognition receptors (PRRs) specifically recognizing certain pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns, which are induced due to tissue damage or cell death [1] . Pathogen-derived nucleic acids, such as unmethylated DNA, viral RNA or cyclic dinucleotides (CDNs), can be detected by various membrane-bound or cytosolic nucleic acid sensors. Toll-like receptors (TLRs), such as TLR3 and TLR9, are the membrane-bound nucleic acid sensors while RIG-I-like receptors (RLRs), absent in melanoma 2 (AIM2)-like receptors (ALRs) and a diverse array of cytosolic DNA/RNA sensors, such as DEAD-box helicase family 41 (DDX41) and cyclic GMP-AMP synthase (cGAS), are responsible for recognizing pathogenic or even host nucleic acids that leaked into the cytosol [1, 2] . Although improper detection of the host-derived nucleic acids is linked to autoimmunity, microbial nucleic acid detection by the PRRs results most commonly in production of type I IFNs from APCs, as well as activation of AIM2-dependent inflammasome pathways to induce IL-18 or IL-1b production and subsequent pyroptotic cell death in some certain cases, like Francisella tularensis infection [1, 3] . Together these responses are crucial for clearance of infection and damaged cells in addition to elicitation of antigen-specific long-term adaptive immune responses by the aid of professional APCs [1, 4] .
Designing efficacious vaccines for infectious diseases or cancer requires use of adjuvants, which target PRRs expressed on APCs and/or aid in efficient antigen/adjuvant delivery to APCs, to achieve potent and long-lasting antigen-specific humoral and cellular immune responses via the mechanisms involving upregulation of co-stimulatory molecules on APCs and enhancement of antigen processing as well as antigen presentation on MHC molecules to B and T cells due to PRR stimulation [1, 4] . Another mechanism by which certain adjuvants, including the well-known adjuvant alum, function is through the induction of endogenous DAMPs, such as DNA, that can activate nucleic acid sensing pathways [5, 6] . Therefore, adjuvants targeting nucleic acid sensors are one of the promising candidates for designing vaccines with high efficacy. Figure 1 summarizes the mode of action of vaccine adjuvants targeting nucleic acid sensing pathways that are discussed in this review.
In this review, we discuss modes of action and applications of nucleic acid-based vaccine adjuvants targeting various cytosolic as well as membrane-bound nucleic acid sensors.
Nucleic acid adjuvants TLR3 agonists
Double-stranded RNA (dsRNA) of viral origin are agonistic ligands for endosomal TLR3 that can induce MyD88-independent but toll/interleukin-1 receptor (TIR)-domain-containing adapter-inducing interferon-b (TRIF)-dependent type I IFN and proinflammatory cytokine production upon RNA sensing [[17 ] ]. Indeed, the synthetic TLR3 agonists, such as polyinosinic-polycytidylic acid (Poly I:C) and PIKA, have been reported to act as robust type 1 adjuvants that can elicit protective antigen-specific CTL, antibody and Th1 type immune responses when included in vaccines for cancer or intracellular pathogens, such as human immunodeficiency virus (HIV) and rabies virus in animal studies [7] [8] [9] [10] [11] . Moreover, poly I:C also functioned as a potent mucosal vaccine adjuvant to successfully induce systemic, as well as mucosal influenza-specific antibody responses that provide protection against not only homologous but also heterologous influenza viruses in mice [12] . Nevertheless, later it was found that poly I:C can activate not only TLR3 but also cytosolic nucleic acid sensors retinoicacid-inducible protein 1 (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), which was the cause of poly I:C's toxicity via cytokine storm induction [13] [14] [15] [16] . Thus, in an attempt to make a safer TLR3-specific adjuvant, Matsumoto et al. developed sODN-dsRNA, which is a synthetic dsRNA conjugated to phosphorothioate oligodeoxynucleotide (ODN) for achieving endosomal delivery without activating cytosolic RNA sensors and they demonstrated that sODN-dsRNA acts as a strong cancer vaccine adjuvant capable of eliciting potent anti-tumor immunity via the mechanisms dependent on NK cells and CTLs without causing significant toxicity in mice [13] . More importantly, recent studies from the same group using this safe TLR3 adjuvant within a cancer vaccine setting (referred to as ARNAX) indicated that in addition to inducing potent Th1 type anti-tumor immunity in mouse tumor models, ARNAX-adjuvanted cancer vaccine can overcome PD-L1 blockade resistance in EG7 tumors that are unresponsive to PD-1/PD-L1 blockade therapy. Furthermore, human peripheral blood mononuclear cell (PBMC) studies investigating antigen-specific CTL expansion upon ARNAX + antigen (cytomegalovirus antigen) stimulation revealed that ARNAX can promote antigen-specific CTL priming, as well as proliferation suggesting high potential of this adjuvant for human cancer vaccines [17 ] .
As another problem with poly I:C was its degradation by nucleases, modified forms of poly I:C, namely poly (I: C 12 U) (Ampligen) and poly ICLC, which showed decreased toxicity while maintaining their adjuvant activities, were developed for clinical use [7, 18] . Clinical trials Mode of action of nucleic acid-based vaccine adjuvants. Cytosolic RNA sensors RIG-I and MDA5 are activated by dsRNA (e.g. Poly I:C) and ssRNA, respectively to trigger IPS-1-dependent and TBK1-dependent type I IFN as well as proinflammatory cytokine production, leading to elicitation of antigen-specific cellular and humoral immune responses. On the other hand, cytosolic DNA sensors, such as cGAS, DDX41, DAI and IFI16, are activated by dsDNA (e.g. B form DNA found in DNA vaccines), to induce STING-dependent and TBK1-dependent, cellular and humoral immune responses, including Th1, Th2, CTL as well as B cell responses, in an antigen-specific manner. Nevertheless, RNA sensing in the endosomal compartments through TLR3 (senses dsRNA) can activate TRIF-dependent and TBK1-dependent signaling pathways for induction of antigen-specific cellular and humoral immune responses. In addition, endosomal nucleic acid sensors TLR7/8 (ssRNA sensor) and TLR9 (unmethylated ssDNA sensor) signal via adapter molecule MyD88 to elicit antigen-specific humoral and cellular immunity, especially Th1 type immune responses. Finally, cytosolic nucleic acids can also activate NLRP3-mediated and AIM2-mediated inflammasome pathways for induction of caspase-1-mediated mature IL-1b production [16, 54, 75, [76] [77] [78] .
for testing the efficacy of Ampligen as an adjuvant for HIV and cancer vaccines confirmed its safety and immunogenicity due to elicitation of antigen-specific Th1 and CTL responses without significant toxicity [18, 19] [20 ] . In addition, vaccination of mice with HIV-derived gag protein conjugated to TLR7/8 agonist resulted in generation of gag-specific Th1 type and CTL responses [23] . Moreover, vaccination of the pigs with diphtheria antigen CRM197 and an oxoadenine-based TLR7/8 agonist elicited antigen-specific cellular and humoral immunity suggesting that TLR7/8 agonists could be promising adjuvant candidates for human vaccines targeting various diseases [21] . Nevertheless, in vitro studies by Ablasser et al. showed that endosomal delivery of ssRNA can robustly activate human monocytes for IFNa and IL-12 production via TLR8, supporting the idea that TLR8 agonists can act as Th1-inducing adjuvants in humans, as well [24] . On the other hand, because of problems such as systemic toxicity due to rapid diffusion of the TLR7/8 agonists, like R848, into the blood upon injection, there are no approved vaccines adjuvanted with TLR7/8 agonists [22] . Indeed, Aldara cream, containing TLR7 agonist imiquimod, is the only TLR7 agonist-based drug approved for clinical use as an anti-tumor agent in patients with precancerous skin lesions and as an antiviral agent for the treatment of external genital warts [22, 25] . Therefore, despite the promising data from preclinical studies, large scale clinical studies are needed to evaluate the adjuvant activity of TLR7/8 agonists in humans.
TLR9 agonists
TLR9 senses infection through the detection of pathogenic DNA with CpG motifs, lacking methylation, in the endosomal compartments and triggers MyD88-dependent type I IFN, as well as proinflammatory cytokine production leading to generation of advantageous Th1 type cellular and humoral immune responses as proven in various preclinical and clinical studies using synthetic CpG oligodeoxynucleotides (ODNs) as systemic or mucosal vaccine adjuvants [1, 26] . Amidst widely studied kinds of CpG ODNs, although D type ODN (or class A ODN) has the ability to robustly activate plasmacytoid DCs (pDCs) for type I IFN production, it only weakly induces antibody production from B cells. In addition, poly-G tails found in D type ODNs results in aggregation in salt solutions due to formation of secondary DNA structures, known as G-quadruplexes thereby limiting clinical applications of D type ODNs. On the contrary, K type ODN (or class B ODN) is a robust activator of B cells for IL-6 and antibody production without aggregate formation. However, although K type ODN, such as K3 CpG, is a weak inducer of type I IFN production from pDCs, it is the only type of CpG ODN available for clinical use [27, 28] .
Clinical trials using K type CpG-adjuvanted malaria, or hepatitis B vaccines revealed that CpG ODN is a safe adjuvant capable of significantly improving the ability of these vaccines to elicit antigen-specific humoral immune responses compared to vaccines without CpG ODN [26, 29, 30] . For instance, CpG-adjuvanted malaria vaccine (also containing alum adjuvant) managed to elicit potent malaria apical membrane antigen 1 (AMA1)-specific antibody responses, which persisted for more than 7 months in a phase I clinical trial [29] . Unfortunately, this vaccine failed to induce Plasmodium falciparum-specific memory B cell responses in semi-immune adults who have experienced multiple malaria infections in Mali [30] . Thus, further clinical trials using TLR9-based adjuvant formulations are required for investigating the potential of TLR9 agonists as vaccine adjuvants.
Modified CpG-based adjuvants
Because of the drawbacks of CpG ODNs described above, many attempts, including chemical modifications of CpG ODNs or combining them either with delivery agents or other well-known adjuvants, such as alum, have been made to enhance their adjuvant effects [25, 26] . Such studies revealed that modified CpG ODN, such as CpG nanorings that have been generated by complexation of CpG with a short cationic peptide derived from HIV (tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] K3-Schizophyllan (K3-SPG) is another example of modified CpG-based adjuvants that have been generated by wrapping SPG (a non-agonistic Dectin-1 ligand) around K3 CpG. As a result, this nanoparticulate CpG-based adjuvant became a robust activator of human PBMCs for IFN production, as well as acting as a potent vaccine adjuvant not only in mice but also in non-human primates to elicit antigen-specific humoral and cellular immune responses that provides protection against lethal influenza challenge in mice [32] . Moreover, the adjuvant effect of the K3-SPG in mice was regulated by IL-12 and type I IFNs, which are produced by CD8a + DCs and pDCs, respectively while IL-12 was dispensable for antigenspecific CTL induction in human PBMCs [34] . Besides, our recent report also showed that use of K3-SPG as a monotherapeutic agent (without antigen) in non-human primates resulted in elicitation of potent antigen-specific memory CTL responses by potently activating pDCs for type I IFN as well as IL-12 production [35 ] . Together these data highlight the potential of K3-SPG as a novel vaccine adjuvant for human vaccines requiring cellular immune responses.
RLR agonists
RIG-I, MDA5 and laboratory of genetics and physiology 2 (LGP2) are the RLRs that sense cytosolic RNA derived from various viruses [1] . RLRs, except LGP2, contain Nterminal caspase activation and recruitment domains (CARDs) that are used for conveying signals to the downstream adaptor molecule interferon promoter stimulator 1 (IPS1), which then induces NF-kB-dependent proinflammatory cytokine and IRF3-dependent and IRF7-dependent type I IFN production [1, 36] . Later, it was found that LGP2, which is crucial for sustaining anti-viral CD8 + T cell responses, is a facilitator of cytosolic RNA sensing by RIG-I and MDA5 via the mechanisms requiring the ATPase domain of LGP2 [36, 37] . Besides, as mentioned in the TLR3 agonists section, synthetic RNA analog Poly I:C is also capable of activating RIG-I and MDA5 signaling pathways in addition to the TLR3 pathway. On the other hand, although a synthetic RLR agonist (KIN1148) has been reported to exert efficacious influenza vaccine adjuvant activities to induce protective humoral and a mixture of regulatory (antigen-specific IL-10 derived from T cells) and Th2 type immune responses, which provide protection of the lungs against influenza-mediated inflammatory tissue damage, in an IRF3-dependent manner, clinical studies are needed for testing the adjuvant effects of RLR agonists in humans [38] .
STING agonists
STING is a key endoplasmic reticulum (ER) resident adaptor molecule situated at the intersection of several cytosolic nucleic acid sensing pathways, such as DDX41, interferon-gamma inducible factor 16 (IFI16) and cGAS, that trigger induction of TBK1-dependent and IRF3-dependent type I IFN production together with NF-kB-dependent proinflammatory cytokines upon detection of nucleic acids derived from pathogens, tumors or even host [2, 39, 40 ,41]. In particular, detection of cytosolic nucleic acids by cGAS leads to production of a secondary signaling molecule known as non-canonical, mammalian, or 2 0 3 0 cyclic GMP-AMP (cGAMP) -48] . For instance, cGAMP, c-di-AMP and cdi-GMP exerted potent mucosal adjuvant activities upon intranasal administration with antigens, such as OVA, b-galactosidase (b-gal) and pneumococcal surface adhesion A (PsaA) [48] [49] [50] [51] . All CDNs were able to induce antigenspecific IgG and IgA responses along with the induction of a balanced antigen-specific Th1/Th2/Th17 response, which provided protection against Streptococcus pneumoniae infection [48] [49] [50] [51] . Furthermore, adjuvant activity of c-di-GMP was mediated by STING-induced antigen uptake augmentation in pinocytosis-efficient DCs [50] . On the other hand, encapsulation of c-di-GMP with PEGylated lipid nanoparticles further improved its adjuvant activity due to more efficient lymph node targeting and retention, as well as preventing the systemic toxicity mediated by blood distribution of c-di-GMP [52] . Moreover, potent CTL-mediated anti-tumor immune responses were elicited by a therapeutic cancer vaccine adjuvanted with this nanoparticulate cdi-GMP (NP-cdGMP) in mouse tumor models of EG-7 and B16 F10 [52] . Besides, Ishikawa et al. showed that adjuvant activity exerted by intramuscular DNA vaccine immunization, which was administered via electroporation, was dependent on STING-mediated type I IFN production [53] . In parallel with their data, Ishii et al. also showed that TBK1-dependent and IRF3-dependent type I IFN production was necessary for adjuvant effects of DNA vaccines to elicit antigen-specific cellular and humoral immunity [54] . In addition, as Suschak et al. reported significantly decreased antigen-specific B and T cell responses upon DNA vaccination (expressing influenza antigen hemagglutinin (HA)) in AIM2 KO mice due to lack of type I IFN production at the vaccination site, it is also possible that AIM2-mediated cell death through pyroptosis could be contributing to the adjuvant effects of DNA vaccines [55] .
Despite the numerous studies showing potential of STING agonists as promising vaccine adjuvants, clinical applications of STING agonists, especially for cancer vaccines, are restricted as 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a synthetic STING agonist, was reported to induce undesired type 2 immunity instead of type 1 immunity that provides protection against intracellular infections, as well as cancer [56] . Indeed, although DMXAA exerted potent anti-tumor effects that are dependent on STING-mediated type I IFN production in murine tumor models, clinical trials using DMXAA as anti-tumor agents in human failed due to inability of DMXAA to activate human STING [57] [58] [59] . On the other hand, as aberrant STING activation can lead to autoimmune and autoinflamatory conditions, such as STING-associated vasculopathy with onset in infancy (SAVI), STING is a double-edged sword that requires delicate handling [60, 61] . Hence, an optimal STING-based vaccine adjuvant should be able to activate all human STING variants irrespective of the polymorphism [62] without causing side effects like autoimmunity or autoinflammation.
Nucleic acid-based combination adjuvants TLR9 + STING agonists
Given the drawbacks of singular use of TLR9 and STING agonists as vaccine adjuvants listed above, we previously combined K3 CpG and cGAMP by simply mixing them in solution and showed a potent synergism between these two adjuvants resulting in IFNg production from NK cells via the mechanisms cooperatively regulated by IL-12 and type I IFNs produced by both pDC and cDCs. In vivo, combination of K3 CpG and cGAMP turned out to be a robust type 1 adjuvant with the ability to induce potent antigen-specific CTL responses while shutting down cGAMP-induced type 2 immunity [46] . In accordance with our data, Yildiz et al. also demonstrated that combination of CpG ODN and c-di-GMP, which was complexed to a cell-penetrating peptide to improve its cellular uptake, became a strong type 1 adjuvant that can provide protective anti-tumor immune responses when used in a therapeutic cancer vaccine in the mouse model of EG-7 [63] . Thus, further studies focusing on the molecular and cellular mechanisms of action of such combinations are required to assess the safety as well as potency of such combination adjuvants.
AS15
Adjuvant systems (GlaxoSmithKline) are a group of adjuvants developed by combining already existing adjuvants, including alum, CpG ODN, QS-21 (saponin-based adjuvant) and MPL (TLR4 agonist), in order to obtain more efficacious adjuvants that can also be used in immunocompromised individuals. Currently, AS03 (squalene-based oilin-water emulsion) is an approved adjuvant for influenza vaccines while AS04 (aluminum hydroxide + MPL) is available for HPV and hepatitis B vaccines [64] . Evidence from clinical trials of cancer, including breast cancer, non-small-cell lung carcinoma (NSCLC) and melanoma patients indicated that AS15, a liposomal formulation containing CpG ODN, MPL and QS-21, is a promising adjuvant capable of inducing advantageous anti-tumor immune responses. In HER2 + breast cancer patients, AS15-adjuvanted vaccine containing recombinant HER2 antigen, was able to induce tumor-specific humoral and cellular immune responses without toxicity (at phase I/II) [65] . However, although the AS15-adjuvanted therapeutic cancer vaccine showed promising adjuvant activities without causing toxicity in melanoma and NSCLC patients (at phases II and III), it was not able to prolong survival of patients with NSCLC at phase III [66 ] . Therefore, additional clinical cancer studies are needed to evaluate adjuvant effect of AS15.
Inducible adjuvants targeting nucleic acid sensors
Certain adjuvants, such as the widely used adjuvant alum, can induce release of DAMPs, including host DNA, at the injection site due to cell death and the detection of these nucleic acids via cytosolic nucleic acid sensing pathways mediate or further enhance the adjuvant effects of those adjuvants as summarized in Figure 2 [67] [68] [69] 70 ]. Specifically, ability of alum to elicit antigen-specific IgE, but not IgG1 responses, was dependent on STING-TBK1-IRF3-induced type I IFN production, which was triggered by cytosolic sensing of the host DNA released from aluminduced dead cells at the injection site while other mechanisms such as alum-mediated induction of non-nucleic acid DAMPs (e.g. IL-1a) may also be involved [67, 71 ]. Likewise, the cationic polysaccharide adjuvant chitosan has been shown to induce antigen-specific Th1 type cellular and humoral immune responses via the mechanisms involving STING-dependent type I IFN production induced by chitosan-mediated mitochondrial damage and subsequent DNA release into the cytosol leading to activation of cytosolic DNA sensor cGAS [70 ] .
Another DAMP-inducing adjuvant is hydroxypropylb-cyclodextrin (HP-b-CD), which has recently been reported to exert potent adjuvant activities when
Immunotherapeutic PAMPs and DAMPs Temizoz, Kuroda and Ishii 109 included in influenza vaccines [68, 69] . Similar to the mode of action of alum, when included in the flu vaccine either as a mucosal or systemic adjuvant, HP-b-CD also induced cell death and subsequent host DNA release at the administration site. In turn, HP-b-CD-induced DNA release contributed to the adjuvant effect of HP-b-CD to elicit protective antigen-specific humoral and Th2 type immune responses as these responses were dependent on TBK1 that is the kinase found downstream of several cytosolic nucleic acid sensing pathways [68, 69] . Indeed, the adjuvant effect of HP-b-CD for influenza split vaccine is currently being tested in a phase I clinical trial in Japan (Clinical Trial Identifier: UMIN000028530). On the other hand, the mucosal adjuvant effect of a lipid based adjuvant, endocine, was mediated via the detection of the RNA released from damaged cells at the vaccination site by TBK1-dependent but STING-independent RNA sensing pathways [72 ] .
Based on the evidence mentioned above, inducible nucleic acid adjuvants that are released due to tissue damage at the vaccination site play key roles in mediating and/or enhancing the immune boosting effects of the DAMP-inducing adjuvants, like alum and chitosan [67, 70 ] . However, promotion of protective cellular and humoral immune responses are important for the efficacy of vaccines whereas continuous release of DAMPs to cause aberrant activation of the immune system may lead to chronic inflammatory or autoimmune diseases, such as nucleic acid sensing-induced and type I IFN-dependent Aicardi-Goutiè res syndrome (AGS), as schematically explained in Figure 3 [6, 73] . Thus, care must be taken when designing vaccines with DAMPinducing adjuvants.
Conclusions
Availability of only a limited number of vaccine adjuvants approved for human use along with the limitations of clinically available adjuvants, such as the inability of alum to induce CTL responses, necessitates development of unique vaccine adjuvants capable of boosting antigenspecific not only humoral but also cellular immune responses [74] . As the current data summarized in this review indicated, adjuvants targeting nucleic acid sensors, including TLRs, RLRs and STING pathway, are strong adjuvant candidates. Notably, preclinical studies showed that modified CpG-based adjuvants or combination adjuvants, such as AS15, K3 CpG + cGAMP, are potent inducers of both humoral and cellular immune responses, especially CTL [46, 31, 32, 65] . On the other hand, endogenous adjuvants/DAMPs (e.g. DNA) that can be induced by certain adjuvants due to tissue damage or cell death are also important for mediating or enhancing the effects of DAMP-inducing adjuvants like alum, HP-b-CD and endocine [67] [68] [69] 72 ]. However, since improper detection of host-derived nucleic acids is also associated with development of autoimmune diseases, care must be taken while designing nucleic acid-based adjuvant formulations [6] . Therefore, we believe that deeper investigation of modes of action and safety of nucleic acid-based adjuvants will reveal efficacious vaccines with unique adjuvant formulations for infectious diseases and cancer. A study revealing that innate immune responses to cytosolic DNA in human macrophages is not mediated only by the cytosolic DNA sensor cGAS. Rather, it requires co-operative action of cGAS and IFI16 that can increase the production of secondary messenger cGAMP by cGAS and also enhances activation of the STING pathway by cGAMP. Therefore, this study hypothesizes that IFI16 may act as a co-factor for cGAS as both cGAS and IFI16 can bind to cytosolic DNA to activate STING-TBK1-IRF3 pathway for interferon production. 
